# US 2023/0405058 A1 · Extracellular vesicles from prevotella

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405058 A1
- Document ID: US20230405058A1
- Status: Published application
- Kind: A1
- Application number: 18/098,377
- Filed: 2023-01-18
- Published: 2023-12-21
- Earliest claimed: 2017-09-08
- Assignees: Evelo Biosciences, Inc.
- Applicants: Evelo Biosciences, Inc.
- Inventors: Brian Goodman; Baundauna Bose; Christopher J.H. Davitt; Sofia M.R. Carlton; William Caffry; Hank Wu
- Web page: https://patentgrep.com/patent/US20230405058A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 39/0216: {Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 1/20: Bacteria; Culture media therefor
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/585: {wherein the target is cancer}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are methods and compositions related to Prevotella EVs useful as therapeutic agents.

## Claims

### Claim at position 1

1-181. (canceled)

### Claim 182

A pharmaceutical composition comprising Prevotella bacterial extracellular vesicles (EVs) isolated from Prevotella Strain B 50329 (NRRL accession number B 50329).

### Claim 183 (depends on 182)

The pharmaceutical composition of claim 182, wherein the composition comprises a pharmaceutically acceptable carrier.

### Claim 184 (depends on 182)

The pharmaceutical composition of claim 182, wherein the composition comprises at least 1×106 Prevotella bacterial extracellular vesicles.

### Claim 185 (depends on 182)

The pharmaceutical composition of claim 182, wherein at least 90% of the total EV and bacteria particles in the pharmaceutical composition are EVs.

### Claim 186 (depends on 182)

The pharmaceutical composition of claim 182, wherein the composition further comprises an additional therapeutic.

### Claim 187 (depends on 186)

The pharmaceutical composition of claim 186, wherein the additional therapeutic is a cancer therapeutic.

### Claim 188 (depends on 187)

The pharmaceutical composition of claim 187, wherein the cancer therapeutic comprises a chemotherapy agent.

### Claim 189 (depends on 187)

The pharmaceutical composition of claim 187, wherein the cancer therapeutic comprises an antibiotic.

### Claim 190 (depends on 187)

The pharmaceutical composition of claim 187, wherein the composition further comprises a prebiotic.

### Claim 191 (depends on 186)

The pharmaceutical composition of claim 186, wherein the additional therapeutic comprises an immunosuppressive agent, a DMARD, a pain-control drug, a steroid, a non-steroidal anti-inflammatory drug (NSAID), or a cytokine antagonist, and combinations thereof.

### Claim 192 (depends on 186)

A method of treating a disease in a subject comprising administering to the subject the pharmaceutical composition of claim 186.

### Claim 193 (depends on 192)

The method of claim 192, wherein the disease is an autoimmune disease, an inflammatory disease, a metabolic disease, or a cancer.

### Claim 194 (depends on 192)

The method of claim 192, wherein the disease is Nonalcoholic Fatty Liver Disease (NAFLD), Primary Sclerosing Cholangitis (PSC) or Nonalcoholic Steatohepatitis (NASH).

### Claim 195 (depends on 192)

The method of claim 192, wherein the disease is atopic dermatitis.

### Claim 196 (depends on 192)

The method of claim 192, wherein the disease is an inflammatory disease.

### Claim 197 (depends on 196)

The method of claim 196, wherein the inflammatory disease is psoriasis.

### Claim 198 (depends on 192)

The method of claim 192, wherein the method further comprises administration of an additional therapeutic to the subject.

### Claim 199 (depends on 198)

The method of claim 198, wherein the disease is cancer and the additional therapeutic is a cancer therapeutic.

### Claim 200 (depends on 199)

The method of claim 199, wherein the cancer therapeutic comprises a chemotherapy agent.

### Claim 201 (depends on 198)

The method of claim 198, wherein the disease is an autoimmune disease or an inflammatory disease and the additional therapeutic comprises an immunosuppressive agent, a DMARD, a pain-control drug, a steroid, a non-steroidal anti-inflammatory drug (NSAID), or a cytokine antagonist, and combinations thereof.
